New study monitors Real-World safety of asthma drug tezepelumab in korea
NCT ID NCT06998095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 210 patients in South Korea who are prescribed Tezepelumab for severe asthma or chronic sinusitis with nasal polyps. Researchers will track side effects and how well the drug controls symptoms in everyday use. The goal is to confirm the drug's safety and effectiveness outside of controlled trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Can a new injection shrink nasal polyps and restore easy breathing?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks